Last reviewed · How we verify

Artesunate-amodiaquine fixed-dose combination

Epicentre · FDA-approved active Small molecule

Artesunate-amodiaquine fixed-dose combination is a Antimalarial combination Small molecule drug developed by Epicentre. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. Also known as: AS-AQ Winthrop® Sanofi Aventis.

Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.

Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.

At a glance

Generic nameArtesunate-amodiaquine fixed-dose combination
Also known asAS-AQ Winthrop® Sanofi Aventis
SponsorEpicentre
Drug classAntimalarial combination
TargetPlasmodium falciparum (multiple parasite targets)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Artesunate, a semi-synthetic artemisinin derivative, generates free radicals that damage parasite proteins and membranes. Amodiaquine, a 4-aminoquinoline, inhibits parasite heme detoxification and disrupts DNA synthesis. The combination provides rapid parasite clearance and reduces the risk of resistance development.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate-amodiaquine fixed-dose combination

What is Artesunate-amodiaquine fixed-dose combination?

Artesunate-amodiaquine fixed-dose combination is a Antimalarial combination drug developed by Epicentre, indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.

How does Artesunate-amodiaquine fixed-dose combination work?

Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.

What is Artesunate-amodiaquine fixed-dose combination used for?

Artesunate-amodiaquine fixed-dose combination is indicated for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.

Who makes Artesunate-amodiaquine fixed-dose combination?

Artesunate-amodiaquine fixed-dose combination is developed and marketed by Epicentre (see full Epicentre pipeline at /company/epicentre).

Is Artesunate-amodiaquine fixed-dose combination also known as anything else?

Artesunate-amodiaquine fixed-dose combination is also known as AS-AQ Winthrop® Sanofi Aventis.

What drug class is Artesunate-amodiaquine fixed-dose combination in?

Artesunate-amodiaquine fixed-dose combination belongs to the Antimalarial combination class. See all Antimalarial combination drugs at /class/antimalarial-combination.

What development phase is Artesunate-amodiaquine fixed-dose combination in?

Artesunate-amodiaquine fixed-dose combination is FDA-approved (marketed).

What are the side effects of Artesunate-amodiaquine fixed-dose combination?

Common side effects of Artesunate-amodiaquine fixed-dose combination include Nausea, Vomiting, Abdominal pain, Headache, Diarrhea, Pruritus.

What does Artesunate-amodiaquine fixed-dose combination target?

Artesunate-amodiaquine fixed-dose combination targets Plasmodium falciparum (multiple parasite targets) and is a Antimalarial combination.

Related